ACE Report Cover
Total hip replacement vs. hip resurfacing for patients with degenerative hip joint disease
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Langue
Download Download Download
Télécharger
Cite this Report Cite this Report Cite this Report
Citer
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoris
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Langue
Download Download Download
Télécharger
Cite this Report Cite this Report Cite this Report
Citer
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoris
ARTHROPLASTY
Total hip replacement vs. hip resurfacing for patients with degenerative hip joint disease .
Verified
This report has been verified by one or more authors of the original publication.

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2014;2(4):4 Bone Joint J. 2013 Nov 1;95-B(11):1464-73
Exclusive Author Interview

Dr. Vendittoli discusses total hip replacement versus hip resurfacing for the treatment of degenerative hip joint disease.

219 hips in 192 patients diagnosed with degenerative hip joint disease, were randomly assigned to treatment with either metal-on-metal hip resurfacing or total hip replacement. The purpose was to compare to two in terms of clinical benefits, metal ion levels, and radiographic outcomes over 8 years after treatment. The results of the study indicated that for young patients suffering from hip joint degeneration, both total hip replacement and hip resurfacing result in similar, improving clinical outcomes and revision rates approximately 8 years postoperatively. Osteolysis was observed more frequently with THR, while higher titanium levels were found in patients who received HR.


Détails du financement de la publication +
Financement:
Industry funded
Sponsor:
Zimmer
Conflits:
Consultant

Risque de partialité

6,5/10

Critères de déclaration

16/20

Indice de fragilité

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Oui = 1

Incertain = 0,5

Non pertinent = 0

Non = 0

L'évaluation des critères de rapport permet d'évaluer la transparence avec laquelle les auteurs rapportent les caractéristiques méthodologiques et les caractéristiques de l'essai dans la publication. L'évaluation est divisée en cinq catégories qui sont présentées ci-dessous.

4/4

Randomization

2/4

Outcome Measurements

4/4

Inclusion / Exclusion

2/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

L'indice de fragilité est un outil qui aide à l'interprétation des résultats significatifs, en fournissant une mesure de la force d'un résultat. L'indice de fragilité représente le nombre d'événements consécutifs qui doivent être ajoutés à un résultat dichotomique pour que le résultat ne soit plus significatif. Un petit nombre représente un résultat plus faible et un grand nombre un résultat plus fort.

Pourquoi cette étude était-elle nécessaire maintenant ?

While total hip replacement (THR) has proven its effectiveness in elderly patients, its overall efficacy in young, active patients is still in question. The amount of patients undergoing THR has rapidly increased over the past decade, with a significant amount of this increase originating from younger male patients. Durability of THRs in younger patients has come into question in recent years, causing a shift in popularity back to metal-on-metal (MoM) hip resurfacing (HR). While there are a wide variety of benefits to HR, such as preservation of femoral neck, avoidance of femoral canal violation, and improvement of future revision surgery outcomes, the comparative efficacy of HR to THA in younger patients remains unknown.

Quelle était la principale question de recherche ?

How does metal-on-metal hip resurfacing compare to total hip replacement in terms of clinical benefits, metal ion levels, and radiographic outcomes approximately 8 years after treatment in patients with degenerative hip joint disease?

Caractéristiques de l'étude +
Population:
192 patients (n=219 hips), between the ages of 18 and 65 years, who were diagnosed with degenerative hip joint disease
Intervention:
Hip Resurfacing Group: Patients in this group received a hybrid Durom CoCr resurfacing implant (Zimmer). As this study is an extension, previous surgical technique, implants, and postoperative treatments were included in the previously published report (Mean age: 49.2 +/- 9.0 years) (n= 04, 93 completed clinical follow up, 40 analyzed for metal ion levels)
Comparaison:
THR Group: Patients in this group received a CLS-Spotorno femoral stem and Allofit acetabular shell with a 28-mm Metasul chromium-cobalt bearing surface inlaid into polyethylene insert, along with a chromium-cobalt femoral head (Mean age: 51.0 +/- 8.6 years) (n=99, 88 completed clinical follow up, 22 analyzed for metal ion levels).
Résultats:
Outcomes assessed were: Western Ontario and McMaster Universities Osteoarthritis Index, Postel-Merle d'Aubigne (PMA) score, University of California, Los Angeles (UCLA) activity score, functional hop and step tests (asked to hop 10 times on operated limb, and climbing up and stepping down a 35 cm step with the operated limb 10 times, measured as very easy, easy, difficult, or impossible by patients), metal ion analysis and radiological outcomes (component positioning, component loosening).
Méthodes:
RCT: Single-Center
Durée de l'intervention:
Approximately 8 years (Outcomes were assessed preoperatively, at 3, 6, 12, and 24 months and, 1, 2, 5, and approximately 8 years (6.6 to 9.3))
Quels sont les résultats importants ?
  • At a mean follow up of 8 years, 4% (4 patients) of THR and 6% (6 patients) of HR were revised (p=0.569). Five patients in the hip resurfacing group experienced a collapse of the femoral head, while the 6th patient underwent revision due to early component migration. Of the 4 patients in the THR group, one revision was due to recurrent dislocation, two due to infection, and one due to traumatic peri-prosthetic femoral fracture (at 6 years).
  • No significant differences were found between the two groups regarding pain/discomfort at any of the measured sites (hip, groin, greater trochanter area, thigh, and buttocks; all p>0.05) for any follow-up . Six resurfacing patients compared to zero in the THR group complained of significant groin pain that lead to investigation or treatment (p=0.015). Two were for femoroacetabular impingement related pain, while the other four were for Brooker's grade 3 heterotopic ossification.
  • Squeaking was reported in two patients who received THR and none in the hip resurfacing group. Three hip resurfacing patients and five THR patients underwent re-operation without implant revision, which was not statistically different between the groups (p=0.428).
  • At final follow-up, mean UCLA score was significantly better in the hip resurfacing group (p=0.035). However, the proportion of patients performing high impact activity (UCLA activity score of 10) was similar (13.8% vs. 19.6% in the THR and hip resurfacing groups, respectively; p=0.301). Hop and step tests showed a trend that favoured hip resurfacing by final follow-up, but these findings did not reach statistical significance (p=0.055 and 0.066, respectively).
  • No difference in WOMAC or PMA scores were found at final-follow up between the groups (p=0.675 and 0.866 respectively), and no significant improvements were observed in either group from 2 years to final follow-up in either group for these outcomes.
  • By 5 year follow-up, Ti level was significant higher in the resurfacing group (2.4 ug/L in the hip resurfacing group vs. 1.6 ug/L in the THR group; p=0.006). No significant difference in Cr (2.1 vs. 1.4 ug/L; p=0.180), or Co levels (0.8 vs. 0.8 ug/L; p=0.614) were found between the groups.
  • At final follow-up, no loose acetabular components were found in either group. Two femoral resurfacing heads, when analyzed at final follow-up, were considered to be loose, and one case femoral neck narrowing > 10% was found. Progressive osteolysis occurred in 30 of 81 THRs (37%) and 2 of 83 hip resurfacings (2.4%) (p<0.001). Impingement between the femoral neck and metallic liner was observed in 5 patients in the THR group.
De quoi dois-je me souvenir en priorité ?

At the average final follow-up of 8 years, no significant difference in revision rates or reoperations without revisions were found between the two groups. Mean UCLA scores were significantly higher in the hip resurfacing group, but similar WOMAC and PMA scores were found between the two by final follow-up. Osteolysis occurred significantly more often the total hip arthroplasty. At 5 year follow-up, mean cobalt and chromium levels were comparable between the groups, and titanium levels were significantly higher with hip resurfacing.

Comment cela affectera-t-il les soins prodigués à mes patients ?

The results of this study indicate that in young patients suffering from hip joint degeneration, both total hip replacement and hip resurfacing result in similarly good clinical outcomes and revision rates approximately 8 years after treatment. Future survival analyses should be conducted if bone preservation in hip resurfacing translates to any favourable outcome over longer follow-up.

AVIS DE NON-RESPONSABILITÉ

Le contenu de cette page est fourni à titre d'information uniquement et n'est pas destiné à remplacer un avis médical, un diagnostic ou un traitement professionnel. Si vous avez besoin d'un traitement médical, demandez toujours l'avis de votre médecin ou rendez-vous au service des urgences le plus proche. Les opinions, croyances et points de vue exprimés par les individus sur le contenu de cette page ne reflètent pas les opinions, croyances et points de vue d'OrthoEvidence.

0 de 4 articles mensuels GRATUITS débloqués
Vous avez atteint votre limite de 4 vues d'articles gratuits ce mois-ci

Accédez à OrthoEvidence pour seulement 1,99 $ par semaine.

Restez informé des dernières données. Annulez à tout moment.
  • Évaluations critiques des derniers essais contrôlés randomisés à fort impact et des revues systématiques en orthopédie.
  • Accès au contenu des podcasts OrthoEvidence, y compris les collaborations avec le Journal of Bone and Joint Surgery, les entretiens avec des chirurgiens de renommée internationale et les tables rondes sur l'actualité et les sujets orthopédiques.
  • Abonnement à The Pulse, une lettre d'information bihebdomadaire fondée sur des données probantes, conçue pour vous aider à prendre de meilleures décisions cliniques.
Upgrade
Close Dialog
Bienvenue à nouveau !
Vous avez oublié votre mot de passe ?
Commencez votre essai GRATUIT dès aujourd'hui !

Votre compte sera affilié à
et inclut un accès gratuit à OrthoEvidence.


OU
Vous avez oublié votre mot de passe ?

OU
Veuillez vérifier votre adresse électronique

Si un compte existe avec l'adresse e-mail fournie, un e-mail de réinitialisation du mot de passe vous sera envoyé. Si vous ne voyez pas d'e-mail, veuillez vérifier votre dossier de spam ou de courrier indésirable.

Pour plus d'assistance, contactez notre équipe d'assistance.

Veuillez vous connecter pour activer cette fonction

Pour accéder à cette fonctionnalité, vous devez être connecté à un compte OrthoEvidence actif. Veuillez vous connecter ou créer un compte d'essai GRATUIT.

Traduire le rapport ACE

OrthoEvidence utilise un service de traduction tiers pour rendre le contenu accessible dans plusieurs langues. Veuillez noter que même si tous les efforts sont faits pour assurer l'exactitude, les traductions ne sont pas toujours parfaites.

Comment citer ce document ACE Report

OrthoEvidence. Total hip replacement vs. hip resurfacing for patients with degenerative hip joint disease. OE Journal. 2014;2(4):4. Available from: https://myorthoevidence.com/AceReport/Show/total-hip-replacement-vs-hip-resurfacing-for-patients-with-degenerative-hip-joint-disease

Copier la citation
Veuillez vous connecter pour activer cette fonction

Pour accéder à cette fonctionnalité, vous devez être connecté à un compte OrthoEvidence actif. Veuillez vous connecter ou créer un compte d'essai GRATUIT.

Fonctionnalité Membre Premium

Pour accéder à cette fonctionnalité, vous devez être connecté à un compte Premium OrthoEvidence.

Partager ACE Report